Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 82

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 85
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
close
Save to Existing Project
Save to a New Project
A Skin Whiting Composition Containing (2Z, 8Z)-matricaria Acid Methyl Ester as an Active Ingredient_INHA UNIV.
Korea Health Industry Development Institute (KHIDI) South Korea flag South Korea
Abstract ID:
A skin whiting composition containing (2Z, 8Z)-matricaria acid methyl ester as an active ingredient...
Contact
Participants
You
Email me a copy of this message

Technology Overview


The core technology of Inha University relates to a skin lightening composition comprising an extract from a erigeron breviscapus, or (2Z,8Z)-matricaria acid methyl ester as an active ingredient.


Background and unmet needs


Melanin plays the roles of absorbing the light UV energy to protect the skin organ below the thick skin from the damage done by UV and protecting the skin from the external harmful factors by holding the harmful oxygen and the free radical generated within the body skin. Moreover, a human skin color is determined on the basis of the melanin quantity inside the skin cell. A person with much melanic pigment has the skin with a brown or black color. On the other hand, a person with little melanic pigment has the skin with a white color.


There are various approaches suppressing the melanin generation including suppression of tyrosinase generation, suppression of tyrosinase activation, reduction of the current melanin, suppression of photooxidation, or promotion of melanin discharge. The kojic acid, arbutin, and their derivatives were developed as the tyrosinase inhibiters but have several disadvantages in terms of stability, side effects, unclear effect and effectiveness, and so on.


As the result of separating, purifying, and identifying the whitening activating ingredients and checking the effect while studying the effective ingredients of the erigeron breviscapus extract stated above on the basis of the patent verifying that the erigeron breviscapus extract has the whitening effect, the inventor of the technology completed the invention by clarifying that the hexane fraction of the extract stated above and the (2Z,8Z)-matricaria acid methyl ester separated from the fraction stated above suppress the melanin generation.


Discovery and Achievements


As the result of examining with the measurement of the optical density the change of the quantity of the melanin generated by processing the hexane fraction and the (2Z,8Z)-matricaria acid methyl ester of the invention after cultivating the melan-a cell, the melanocyte, to measure the whitening effect, the hexane fraction showed the effect of suppressing the melanin generation in the low concentration compared to a non-processed group that is a negative contract group, and the (2Z,8Z)-matricaria acid methyl ester showed the effect of suppressing the melanin generation in the low concentration compared to the Phenylthiourea (PTU) known to be a positive contract group and to be the material suppressing the melanin generation and to the non-processed group that is a negative contract group.

GO PREMIUM TO GET PATENT INFORMATION
Type of Business Relationship Sought
US20090214454A1, EP2092837B1
FEATURED
Last Updated Jun 2016
Technology Type THERAPEUTIC
Phase of Development EARLY STAGE
GOVERNMENT INSTITUTE